Myriad Genetics Inc: (NASD: MYGN)
$26.44
-0.18 (-0.68%)
Volume 3,547,986
Jun 18 04:00 PM ET
Zacks Rank: 2-Buy 
| #2 |
Financial Overview
P/E
| P/E (F1) | 16.35 |
| Trailing 12 Months | 16.85 |
| PEG Ratio | 1.16 |
Price Ratios
| Price/Book | 3.23 |
| Price/Cash Flow | 18.64 |
| Price / Sales | 3.71 |
Current Ratio
| 03-31-13 | 8.35 |
| 12-31-12 | 10.06 |
| 09-30-12 | 7.59 |
Net Margin
| 03-31-13 | 23.11 |
| 12-31-12 | 22.73 |
| 09-30-12 | 22.58 |
Inventory Turnover
| 03-31-13 | 7.49 |
| 12-31-12 | 6.64 |
| 09-30-12 | 6.31 |
EPS Growth
| vs. Previous Year | 35.29 |
| vs. Previous Quarter | 9.52 |
ROE
| 03-31-13 | 20.35 |
| 12-31-12 | 19.17 |
| 09-30-12 | 18.45 |
Quick Ratio
| 03-31-13 | 8.22 |
| 12-31-12 | 9.83 |
| 09-30-12 | 7.40 |
Pre-Tax Margin
| 03-31-13 | 37.50 |
| 12-31-12 | 37.18 |
| 09-30-12 | 37.10 |
Debt-to-Equity
| 03-31-13 | 0.00 |
| 12-31-12 | 0.00 |
| 09-30-12 | 0.00 |
Sales Growth
| vs. Previous Year | 20.57 |
| vs. Previous Quarter | 4.92 |
ROA
| 03-31-13 | 18.62 |
| 12-31-12 | 17.64 |
| 09-30-12 | 17.02 |
Operating Margin
| 03-31-13 | 23.11 |
| 12-31-12 | 22.73 |
| 09-30-12 | 22.58 |
Book Value
| 03-31-13 | 8.25 |
| 12-31-12 | 8.13 |
| 09-30-12 | 7.78 |
Debt to Capital
| 03-31-13 | 0.00 |
| 12-31-12 | 0.00 |
| 09-30-12 | 0.00 |
